Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LMY004
MIFTS: 58

Leiomyosarcoma

Categories: Rare diseases, Cancer diseases, Muscle diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Leiomyosarcoma

About this section

MalaCards integrated aliases for Leiomyosarcoma:

Name: Leiomyosarcoma 12 76 53 59 55 6 44 15 73
Leiomyosarcomas 12

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Muscle diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:1967
MeSH 44 D007890
NCIt 50 C3158
Orphanet 59 ORPHA64720
MESH via Orphanet 45 D007890
UMLS via Orphanet 74 C0023269
ICD10 via Orphanet 34 C49.9
UMLS 73 C0023269
Sources

Summaries for Leiomyosarcoma

About this section
NIH Rare Diseases : 53 Leiomyosarcoma is a rare cancerous tumor that consists of smooth (involuntary) muscle cells. Leiomyosarcoma is a type of sarcoma. It spreads through the blood stream and can affect the lungs, liver, blood vessels, or any other soft tissue in the body. The exact cause of leiomyosarcoma is not known, although genetic and environmental factors appear to be involved. It is most often found in the uterus or abdomen.

MalaCards based summary : Leiomyosarcoma, also known as leiomyosarcomas, is related to cutaneous leiomyosarcoma and epithelioid leiomyosarcoma. An important gene associated with Leiomyosarcoma is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways/superpathways are ERK Signaling and Phospholipase-C Pathway. The drugs Oxaliplatin and Liver Extracts have been mentioned in the context of this disorder. Affiliated tissues include uterus, smooth muscle and lung, and related phenotypes are Decreased viability in esophageal squamous lineage and cellular

Disease Ontology : 12 A malignant smooth muscle cancer that can arise almost anywhere in the body, but is most common in the uterus, abdomen, or pelvis.

Wikipedia : 76 Leiomyosarcoma, also referred to as LMS, is a malignant (cancerous) smooth muscle tumor. A benign tumor... more...

Sources

Related Diseases for Leiomyosarcoma

About this section

Diseases in the Leiomyosarcoma family:

Inflammatory Leiomyosarcoma

Diseases related to Leiomyosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 429)
# Related Disease Score Top Affiliating Genes
1 cutaneous leiomyosarcoma 34.2 ACTC1 DES FH
2 epithelioid leiomyosarcoma 33.6 ACTC1 DES ENO2 VIM
3 myxoid leiomyosarcoma 33.4 ACTC1 PGR
4 small intestine leiomyosarcoma 33.2 IGF2 KIT
5 gastric leiomyosarcoma 32.4 ENO2 IGF2 KIT PDGFRA
6 smooth muscle tumor 30.7 ACTC1 DES KIT PGR VIM
7 fibrous histiocytoma 30.6 ACTC1 DES S100B VIM
8 leiomyomatosis 30.5 FH MED12 PGR
9 uterine carcinosarcoma 30.5 KIT PGR TP53
10 bizarre leiomyoma 30.5 ACTC1 MED12 PGR
11 malignant giant cell tumor 30.4 ACTC1 S100B TP53
12 sarcoma, synovial 30.3 DES KIT MDM2 VIM
13 cystadenocarcinoma 30.2 PGR TP53 VIM
14 mesenchymoma 30.2 DES MB MDM2
15 syringocystadenoma papilliferum 30.2 ACTC1 DES S100B VIM
16 desmoid tumor 29.8 KIT PDGFRA PDGFRB
17 myxoid liposarcoma 29.8 CDK4 MDM2 TP53
18 dedifferentiated liposarcoma 29.8 ACTC1 CDK4 DES MDM2 TP53
19 angiomyoma 29.8 ENO2 KIT MB
20 teratoma 29.8 ACTC1 ENO2 KIT TP53
21 epulis 29.7 DES ENO2 PGR VIM
22 granular cell tumor 29.7 DES ENO2 S100B VIM
23 glomus tumor 29.6 ACTC1 DES ENO2 TP53 VIM
24 endosalpingiosis 29.6 PGR WT1
25 histiocytoma 29.6 CDK4 KIT MB MDM2 TP53
26 malignant fibroxanthoma 29.5 ACTC1 CDK4 DES MDM2 S100B VIM
27 liposarcoma 29.5 CDK4 DES MB MDM2 TP53 VIM
28 neurilemmoma 29.0 DES ENO2 KIT PDGFRA S100B VIM
29 glioblastoma multiforme 28.6 CDK4 MDM2 PDGFRA PDGFRB TP53
30 endometrial stromal sarcoma 28.5 ACTC1 DES KIT MB PDGFRB PGR
31 glioblastoma 28.4 CDK4 MDM2 PDGFRA PDGFRB TP53
32 leiomyoma 28.3 ACTC1 DES FH IGF2 KIT MED12
33 embryonal rhabdomyosarcoma 28.3 CDK4 DES IGF2 MB MYOG
34 uterine sarcoma 28.1 DES KIT MB MDM2 PDGFRB WT1
35 renal cell carcinoma, nonpapillary 28.0 FH KIT PDGFRB S100A1 VIM WT1
36 dermatofibrosarcoma protuberans 28.0 ACTC1 DES KIT PDGFRA PDGFRB S100B
37 gastrointestinal stromal tumor 27.8 ACTC1 DES ENO2 IGF2 KIT PDGFRA
38 malignant mesenchymoma 27.6 CDK4 DES KIT MB MDM2 MYOG
39 rhabdomyosarcoma 25.6 ACTC1 CDK4 DES ENO2 IGF2 MB
40 lung leiomyosarcoma 12.2
41 uterus leiomyosarcoma 12.2
42 liver leiomyosarcoma 12.2
43 colon leiomyosarcoma 12.2
44 kidney leiomyosarcoma 12.1
45 extrahepatic bile duct leiomyosarcoma 12.1
46 anus leiomyosarcoma 12.0
47 mediastinum leiomyosarcoma 12.0
48 pulmonary artery leiomyosarcoma 12.0
49 retroperitoneal leiomyosarcoma 12.0
50 breast leiomyosarcoma 12.0

Graphical network of the top 20 diseases related to Leiomyosarcoma:



Diseases related to Leiomyosarcoma
Sources

Symptoms & Phenotypes for Leiomyosarcoma

About this section

GenomeRNAi Phenotypes related to Leiomyosarcoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.32 CAPN6 DES KIT MB MED12 PDGFRA

MGI Mouse Phenotypes related to Leiomyosarcoma:

46 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.52 TP53 PGR S100A1 WT1 VIM DES
2 cardiovascular system MP:0005385 10.47 TP53 PGR S100A1 WT1 VIM DES
3 behavior/neurological MP:0005386 10.45 S100A1 S100B TP53 PGR VIM DES
4 homeostasis/metabolism MP:0005376 10.45 S100A1 S100B TP53 PGR WT1 VIM
5 growth/size/body region MP:0005378 10.39 TP53 WT1 IGF2 ACTC1 CAPN6 ENO2
6 embryo MP:0005380 10.38 TP53 PGR WT1 VIM CDK4 IGF2
7 mortality/aging MP:0010768 10.38 TP53 PGR WT1 VIM DES ACTC1
8 muscle MP:0005369 10.36 VIM TP53 PGR S100A1 WT1 DES
9 hematopoietic system MP:0005397 10.28 PDGFRB PGR TP53 WT1 VIM CDK4
10 craniofacial MP:0005382 10.24 TP53 CAPN6 ENO2 IGF2 KIT MDM2
11 endocrine/exocrine gland MP:0005379 10.21 PDGFRB PGR TP53 WT1 CDK4 KIT
12 integument MP:0010771 10.21 S100B PGR TP53 IGF2 CDK4 KIT
13 digestive/alimentary MP:0005381 10.18 PDGFRB TP53 CAPN6 CDK4 IGF2 KIT
14 normal MP:0002873 10.18 S100A1 S100B TP53 PGR WT1 ACTC1
15 limbs/digits/tail MP:0005371 10.1 PDGFRB PGR TP53 IGF2 KIT MDM2
16 no phenotypic analysis MP:0003012 10.01 PGR TP53 WT1 IGF2 KIT MDM2
17 neoplasm MP:0002006 9.98 PGR TP53 WT1 CDK4 MDM2 KIT
18 renal/urinary system MP:0005367 9.91 TP53 WT1 IGF2 FH CDK4 KIT
19 reproductive system MP:0005389 9.85 PDGFRB PGR TP53 WT1 VIM CDK4
20 pigmentation MP:0001186 9.72 TP53 CDK4 KIT MDM2 PDGFRA
21 respiratory system MP:0005388 9.65 S100A1 TP53 WT1 VIM ENO2 IGF2
22 skeleton MP:0005390 9.28 PDGFRB PGR TP53 KIT MDM2 IGF2
Sources

Drugs & Therapeutics for Leiomyosarcoma

About this section

Drugs for Leiomyosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 173)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 1 61825-94-3 5310940 9887054 43805 6857599
2 Liver Extracts Phase 4,Phase 3,Phase 1,Not Applicable
3 Cola Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
4
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
5
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
6
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
7
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
8
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
9
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
10
Trabectedin Approved, Investigational Phase 3,Phase 2,Phase 1 114899-77-3 108150
11
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
12
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
13
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 498142 38904
14
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
15
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 2019 457193
16
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
17
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
18
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
19
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 50-02-2 5743
20
Ondansetron Approved Phase 3 99614-02-5 4595
21
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
22
Cyproheptadine Approved Phase 3 129-03-3 2913
23
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
24
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
25 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
26 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
27 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
28 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
29 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
30
Isophosphamide mustard Phase 3,Phase 2,Phase 1,Not Applicable 0
31 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
32 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
33 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
34 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
35 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
36 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
37 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
38 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
39 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
40 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
41 Pharmaceutical Solutions Phase 3,Not Applicable
42 Etoposide phosphate Phase 3,Phase 2
43 Antirheumatic Agents Phase 3,Phase 2,Phase 1
44 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
45 Adjuvants, Anesthesia Phase 3
46 Analgesics Phase 3,Phase 1
47 Analgesics, Opioid Phase 3
48 Anesthetics Phase 3
49 Anesthetics, General Phase 3
50 Anesthetics, Intravenous Phase 3

Interventional clinical trials:

(show top 50) (show all 152)
# Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
3 A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Completed NCT01692678 Phase 3 Trabectedin;Dacarbazine
4 A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma Completed NCT01343277 Phase 3 Trabectedin;Dacarbazine
5 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
6 Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus Completed NCT00002459 Phase 3
7 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
8 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
9 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
10 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
11 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
12 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
13 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
14 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
15 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3 dexamethasone;ondansetron
16 Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy Completed NCT00753688 Phase 3 PAZOPANIB;Placebo
17 A Phase III Trial of Anlotinib in Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma Recruiting NCT03016819 Phase 3 AL 3818;Dacarbazine
18 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
19 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
20 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Recruiting NCT01344018 Phase 3
21 Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Active, not recruiting NCT01533207 Phase 3 Docetaxel;Doxorubicin Hydrochloride;Gemcitabine Hydrochloride
22 A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02451943 Phase 3 Olaratumab;Doxorubicin;Placebo
23 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
24 Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma Not yet recruiting NCT02997358 Phase 3 Doxorubicin;Trabectedin
25 Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma Terminated NCT01012297 Phase 3 Docetaxel;Gemcitabine Hydrochloride
26 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
27 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
28 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Unknown status NCT02203760 Phase 2 Pazopanib plus Gemcitabine;Pazopanib
29 Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patients With Metastatic or Relapsed Uterine or Soft Tissue Leiomyosarcomas Unknown status NCT01442662 Phase 2 pazopanib + gemcitabine
30 Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum Unknown status NCT02587169 Phase 1, Phase 2 Nilotinib-adriamycin
31 Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma Unknown status NCT00033709 Phase 2 temozolomide;thalidomide
32 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
33 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
34 Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma Completed NCT02249702 Phase 2 gemcitabine + docetaxel;trabectedin
35 Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma Completed NCT02131480 Phase 2 Doxorubicin;Trabectedin
36 SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma Completed NCT02303262 Phase 2 Mocetinostat;Gemcitabine
37 Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma Completed NCT00856050 Phase 2 letrozole
38 Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT01637961 Phase 2 Alisertib
39 Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma Completed NCT00282087 Phase 2 gemcitabine, docetaxel, doxorubicin
40 Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy Completed NCT01220609 Phase 2 Ixabepilone
41 Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT00378911 Phase 2 sunitinib malate
42 Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus Completed NCT00379145 Phase 2 trabectedin
43 Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma Completed NCT00310518 Phase 2 ARQ 501
44 Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma Completed NCT00101127 Phase 2 docetaxel;gemcitabine hydrochloride
45 Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma Completed NCT00227669 Phase 2 docetaxel;gemcitabine hydrochloride
46 Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma Completed NCT00004066 Phase 2 docetaxel;gemcitabine hydrochloride
47 A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer Completed NCT00060944 Phase 2 Yondelis;Yondelis;Dexamethasone;Dexamethasone
48 Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus Completed NCT00025220 Phase 2 Thalidomide
49 Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus Completed NCT00031629 Phase 2 Docetaxel;Gemcitabine Hydrochloride
50 Chemotherapy in Treating Patients With Sarcoma of the Uterus Completed NCT00005643 Phase 2 pegylated liposomal doxorubicin hydrochloride

Search NIH Clinical Center for Leiomyosarcoma

Cochrane evidence based reviews: leiomyosarcoma

Sources

Genetic Tests for Leiomyosarcoma

About this section
Sources

Anatomical Context for Leiomyosarcoma

About this section

MalaCards organs/tissues related to Leiomyosarcoma:

41
Uterus, Smooth Muscle, Lung, Liver, Bone, Colon, Breast
Sources

Publications for Leiomyosarcoma

About this section

Articles related to Leiomyosarcoma:

(show top 50) (show all 1302)
# Title Authors Year
1
Recurrence of Primary Vascular Leiomyosarcoma Five Years after Initial Diagnosis in the Lower Extremity. ( 29971175 )
2018
2
Primary leiomyosarcoma in the colon: A case report. ( 29443772 )
2018
3
Radiation-induced leiomyosarcoma of the rectum after cervical cancer treatment. ( 29439826 )
2018
4
Leiomyosarcoma of the stomach with metastasis to the liver: a case report with review of the literature. ( 29379638 )
2018
5
Denosumab as a potential therapeutic option for leiomyosarcoma with osteoclast-like giant cells: A case report. ( 29387393 )
2018
6
Delayed diagnosis of dermal leiomyosarcoma mimicking keloid scar. ( 29374640 )
2018
7
Coexistence of Cervical Leiomyosarcoma and Gastric-Type Adenocarcinoma In Situ with Extensive Extension to the Endometrium and Fallopian Tube. ( 29670794 )
2018
8
Cancer-testis antigens are predominantly expressed in uterine leiomyosarcoma compared with non-uterine leiomyosarcoma. ( 29399140 )
2018
9
Leiomyosarcoma of the great saphenous vein (vena saphena magna) with granular cell change: Report of a superficial neoplasm. ( 29068077 )
2018
10
Options for Adjuvant Therapy for Uterine Leiomyosarcoma. ( 29417238 )
2018
11
Role of bevacizumab in uterine leiomyosarcoma. ( 29759566 )
2018
12
Partial cystectomy for a primary locally advanced leiomyosarcoma of the bladder: a case report and review of the literature. ( 29744079 )
2018
13
Treatment with epigenetic agents profoundly inhibits tumor growth in leiomyosarcoma. ( 29721210 )
2018
14
Primary leiomyosarcoma of the fallopian tube: Three case reports and review of the literature. ( 29880185 )
2018
15
Neuropilin 1 in uterine leiomyosarcoma. Clinical and pathological analysis. ( 29411340 )
2018
16
Primary pulmonary leiomyosarcoma: A population-based study. ( 29413053 )
2018
17
A rare primary leiomyosarcoma of the parotid gland: A case report and literature review. ( 29395283 )
2018
18
Establishment and characterization of patient-derived xenograft and its cell line of primary leiomyosarcoma of bone. ( 29845452 )
2018
19
Review of the literature laparoscopic surgery for metastatic hepatic leiomyosarcoma associated with smooth muscle tumor of uncertain malignant potential: Case report. ( 29713398 )
2018
20
Resection of a Perirectal Leiomyosarcoma via a Posterior Transcoccygeal Approach. ( 29981026 )
2018
21
Pazopanib-mediated Long-term Disease Stabilization after Local Recurrence and Distant Metastasis of Primary Intracranial Leiomyosarcoma: A Case Report on the Efficacy of Pazopanib as a Salvage Therapy. ( 29354331 )
2018
22
Pulmonary artery leiomyosarcoma: A clinical dilemma. ( 29487255 )
2018
23
Metastatic leiomyosarcoma presenting as a lung mass with left atrial extension: case report and anesthetic management. ( 29403281 )
2018
24
Anterior mediastinal leiomyosarcoma mimicking thymoma: A case report. ( 29924013 )
2018
25
Long-Term Progression-Free Survival in a Patient with Metastatic Leiomyosarcoma of the Inguinal Region Treated with Trabectedin. ( 29805376 )
2018
26
Primary breast leiomyosarcoma with metastases to the lung in a young adult: Case report and literature review. ( 29705677 )
2018
27
Posterior reversible encephalopathy syndrome (PRES) in mesenteric leiomyosarcoma: A case report. ( 29980031 )
2018
28
Primary Leiomyosarcoma of the Colon: A Report of Two Cases, Review of the Literature, and Association with Immunosuppression for IBD and Rheumatoid Arthritis. ( 29780656 )
2018
29
Diagnosis and management of rare inferior vena cava leiomyosarcoma guided by a novel minimally invasive vascular biopsy technique. ( 29411530 )
2018
30
Organ preservation in leiomyosarcoma bladder: Case report and review of literature. ( 29719342 )
2018
31
A Case Report of Metastatic Primary Thyroid Leiomyosarcoma Treated with Pazopanib. ( 29431311 )
2018
32
The prevalence of occult leiomyosarcoma in women undergoing presumed fibroid surgery and outcomes after morcellation. ( 29251674 )
2018
33
Uterine smooth muscle tumours with hyperintense area on T<sub>1</sub>A weighted images: differentiation between leiomyosarcomas and leiomyomas. ( 29308922 )
2018
34
Functionality of the Tumor Suppressor <i>microRNA-1</i> in Malignant Tissue and Cell Line Cells of Uterine Leiomyosarcoma. ( 29491084 )
2018
35
Malignant transformation of uterine leiomyoma to myxoid leiomyosarcoma after morcellation associated with <i>ALK</i> rearrangement and loss of 14q. ( 29963223 )
2018
36
Primary intracranial leiomyosarcoma with intra-tumoral hemorrhage: Case report and review of literature. ( 29753901 )
2018
37
Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma. ( 29660202 )
2018
38
Multimodality management of leiomyosarcoma of the cervix. ( 29743950 )
2018
39
Cutaneous leiomyosarcoma on the face. ( 29723357 )
2018
40
Identification of key genes and pathways in uterine leiomyosarcoma through bioinformatics analysis. ( 29844831 )
2018
41
Primary Renal Leiomyosarcoma Presenting with Subcutaneous and Osseous Metastases: Staging and Follow-Up with 18F-FDG PET/CT. ( 29391915 )
2018
42
Primary cutaneous vascular leiomyosarcoma: A rare subtype of leiomyosarcoma of the skin. ( 29740853 )
2018
43
Primary Cardiac Leiomyosarcoma: A 27-Month Survival with Surgery and Chemotherapy. ( 28781298 )
2017
44
Combination of gemcitabine and docetaxel regresses both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model. ( 28426279 )
2017
45
Orbital leiomyosarcoma metastasis presenting prior to diagnosis of the primary tumor. ( 29403338 )
2017
46
Retroperitoneal leiomyosarcoma: a case report. ( 29767887 )
2017
47
Retromammary fat, axillary and arm metastases from a retroperitoneal leiomyosarcoma: report of a case with an indolent behaviour. ( 29225685 )
2017
48
Right atrial extension of a giant retroperitoneal leiomyosarcoma. ( 28469124 )
2017
49
Myosin regulatory light chain phosphorylation is associated with leiomyosarcoma development. ( 28618653 )
2017
50
Primary Pulmonary Vein Leiomyosarcoma With Left Atrial Extension. ( 29195579 )
2017
Sources

Variations for Leiomyosarcoma

About this section

Cosmic variations for Leiomyosarcoma:

9
(show top 50) (show all 684)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6987318 ZFHX3 soft tissue,smooth muscle,leiomyosarcoma,NS c.2513A>G p.N838S 16:72957633-72957633 9
2 COSM212945 XPO1 soft tissue,smooth muscle,leiomyosarcoma,NS c.782G>A p.R261Q 2:61496985-61496985 9
3 COSM6986268 TSC1 soft tissue,smooth muscle,leiomyosarcoma,NS c.1079C>A p.T360N 9:132911064-132911064 9
4 COSM10648 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.524G>A p.R175H 17:7675088-7675088 9
5 COSM10704 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.844C>T p.R282W 17:7673776-7673776 9
6 COSM6900 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.376-1G>A p.? 17:7675237-7675237 9
7 COSM44732 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.512A>G p.E171G 17:7675100-7675100 9
8 COSM44327 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.518T>C p.V173A 17:7675094-7675094 9
9 COSM43615 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.473G>C p.R158P 17:7675139-7675139 9
10 COSM307332 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.976G>A p.E326K 17:7673552-7673552 9
11 COSM44057 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.517G>C p.V173L 17:7675095-7675095 9
12 COSM1640842 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.641A>C p.H214P 17:7674890-7674890 9
13 COSM10790 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.455C>T p.P152L 17:7675157-7675157 9
14 COSM11224 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.394A>C p.K132Q 17:7675218-7675218 9
15 COSM43878 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.427G>A p.V143M 17:7675185-7675185 9
16 COSM43632 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.493C>T p.Q165* 17:7675119-7675119 9
17 COSM10705 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.586C>T p.R196* 17:7674945-7674945 9
18 COSM10662 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.743G>A p.R248Q 17:7674220-7674220 9
19 COSM44238 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.631A>G p.T211A 17:7674900-7674900 9
20 COSM10735 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.638G>A p.R213Q 17:7674893-7674893 9
21 COSM10667 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.646G>A p.V216M 17:7674885-7674885 9
22 COSM44610 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.97-2A>T p.? 17:7676274-7676274 9
23 COSM43700 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.712T>A p.C238S 17:7674251-7674251 9
24 COSM43949 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.401T>G p.F134C 17:7675211-7675211 9
25 COSM43753 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.560-1G>A p.? 17:7674972-7674972 9
26 COSM45135 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.673-1G>T p.? 17:7674291-7674291 9
27 COSM13745 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.994-1G>C p.? 17:7670716-7670716 9
28 COSM10758 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.659A>G p.Y220C 17:7674872-7674872 9
29 COSM10656 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.742C>T p.R248W 17:7674221-7674221 9
30 COSM11476 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.452C>A p.P151H 17:7675160-7675160 9
31 COSM44537 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.595G>T p.G199* 17:7674936-7674936 9
32 COSM10690 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.473G>A p.R158H 17:7675139-7675139 9
33 COSM11073 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.1024C>T p.R342* 17:7670685-7670685 9
34 COSM10905 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.451C>T p.P151S 17:7675161-7675161 9
35 COSM10768 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.535C>T p.H179Y 17:7675077-7675077 9
36 COSM10663 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.916C>T p.R306* 17:7673704-7673704 9
37 COSM44415 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.711G>C p.M237I 17:7674252-7674252 9
38 COSM43989 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.596G>A p.G199E 17:7674935-7674935 9
39 COSM21585 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.376-2A>T p.? 17:7675238-7675238 9
40 COSM10654 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.637C>T p.R213* 17:7674894-7674894 9
41 COSM10788 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.764T>G p.I255S 17:7674199-7674199 9
42 COSM10726 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.856G>A p.E286K 17:7673764-7673764 9
43 COSM43778 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.713G>T p.C238F 17:7674250-7674250 9
44 COSM44956 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.808T>G p.F270V 17:7673812-7673812 9
45 COSM11658 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.955A>T p.K319* 17:7673573-7673573 9
46 COSM44960 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.708C>G p.Y236* 17:7674255-7674255 9
47 COSM3849376 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.753C>G p.I251M 17:7674210-7674210 9
48 COSM44567 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.647T>C p.V216A 17:7674884-7674884 9
49 COSM43596 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.841G>A p.D281N 17:7673779-7673779 9
50 COSM44076 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.655C>T p.P219S 17:7674876-7674876 9

Copy number variations for Leiomyosarcoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 102985 16 58400001 69400000 Loss Leiomyosarcoma
Sources

Expression for Leiomyosarcoma

About this section
Search GEO for disease gene expression data for Leiomyosarcoma.
Sources

Pathways for Leiomyosarcoma

About this section

Pathways related to Leiomyosarcoma according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 64
Show member pathways
 13.77 CAPN6 CDK4 DES IGF2 KIT MDM2
2
Phospholipase-C Pathway 64
Show member pathways
 12.92 IGF2 KIT MDM2 PDGFRA PDGFRB TP53
3
Endometrial cancer 37
Show member pathways
 12.7 CDK4 KIT MDM2 PDGFRA PDGFRB TP53
4
PI3K-Akt signaling pathway 37
Show member pathways
 12.69 CDK4 IGF2 KIT MDM2 PDGFRA PDGFRB
5
Glioma 37
Show member pathways
 12.66 CDK4 MDM2 PDGFRA PDGFRB TP53
6
MAPK signaling pathway 1 37
12.64 IGF2 KIT PDGFRA PDGFRB TP53
7
Gastric cancer 37
Show member pathways
 12.63 CDK4 IGF2 KIT PGR TP53
8
Downstream signaling events of B Cell Receptor (BCR) 66
Show member pathways
 12.57 KIT MDM2 PDGFRA PDGFRB TP53
9
MicroRNAs in cancer 37
12.33 MDM2 PDGFRA PDGFRB TP53 VIM
10
HTLV-I infection 37
12.32 CDK4 PDGFRA PDGFRB TP53
11
Pathways in cancer 37
12.28 CDK4 FH IGF2 KIT MDM2 PDGFRA
12
Apoptosis Pathway 72
Show member pathways
 12.22 CAPN6 MDM2 PDGFRA PDGFRB TP53
13
MAPK Signaling: Mitogen Stimulation Pathway 65
Show member pathways
 11.97 CDK4 PDGFRA PDGFRB
14
AKT Signaling Pathway 67
11.92 CDK4 MDM2 PDGFRA PDGFRB TP53
15
Retinoblastoma (RB) in Cancer 1
11.74 CDK4 MDM2 TP53
16
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.68 PDGFRA S100B VIM
17
Bladder cancer 37 1
11.62 CDK4 MDM2 TP53
18
Striated Muscle Contraction 1 66
11.59 ACTC1 DES VIM
19
Gefitinib Pathway, Pharmacokinetics 61
Show member pathways
 11.49 KIT PDGFRA PDGFRB
20
Central carbon metabolism in cancer 37
11.37 KIT PDGFRA PDGFRB TP53
21
Integrated Cancer Pathway 1
11.35 CDK4 MDM2 TP53
22
DNA damage_ATM/ATR regulation of G1/S checkpoint 22
11.31 CDK4 MDM2 TP53
23
Cardiac Progenitor Differentiation 1
11.18 ACTC1 IGF2 KIT PDGFRA
24
Glioblastoma Multiforme 64
11.15 CDK4 IGF2 MDM2 PDGFRA PDGFRB TP53
25
Oncogene Induced Senescence 66
11.11 CDK4 MDM2 TP53
Sources

GO Terms for Leiomyosarcoma

About this section

Cellular components related to Leiomyosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.55 ACTC1 CAPN6 CDK4 DES ENO2 FH

Biological processes related to Leiomyosarcoma according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.95 ACTC1 KIT MDM2 TP53 VIM
2 heart development GO:0007507 9.91 MB MDM2 MED12 WT1
3 positive regulation of protein kinase B signaling GO:0051897 9.81 IGF2 KIT PDGFRA PDGFRB
4 positive regulation of MAPK cascade GO:0043410 9.8 IGF2 KIT PDGFRA PDGFRB
5 cell chemotaxis GO:0060326 9.77 KIT PDGFRA PDGFRB
6 positive regulation of kinase activity GO:0033674 9.76 KIT PDGFRA PDGFRB
7 positive regulation of fibroblast proliferation GO:0048146 9.71 CDK4 PDGFRA PDGFRB
8 positive regulation of cell proliferation GO:0008284 9.7 CDK4 IGF2 KIT MDM2 PDGFRA PDGFRB
9 muscle filament sliding GO:0030049 9.65 ACTC1 DES VIM
10 negative regulation of platelet-derived growth factor receptor-beta signaling pathway GO:2000587 9.58 PDGFRA PDGFRB
11 metanephric mesenchyme development GO:0072075 9.57 PDGFRB WT1
12 retina vasculature development in camera-type eye GO:0061298 9.56 PDGFRA PDGFRB
13 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.56 IGF2 KIT PDGFRA PDGFRB
14 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.54 KIT PDGFRA PDGFRB
15 metanephric S-shaped body morphogenesis GO:0072284 9.52 PDGFRB WT1
16 cardiac myofibril assembly GO:0055003 9.5 ACTC1 PDGFRA PDGFRB
17 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.46 PDGFRA PDGFRB
18 cellular response to actinomycin D GO:0072717 9.43 MDM2 TP53
19 metanephric glomerular capillary formation GO:0072277 9.4 PDGFRA PDGFRB
20 negative regulation of apoptotic process GO:0043066 9.23 ACTC1 IGF2 KIT MDM2 PDGFRA PDGFRB
21 positive regulation of phospholipase C activity GO:0010863 9.13 KIT PDGFRA PDGFRB
22 multicellular organism development GO:0007275 10.14 CDK4 IGF2 KIT MYOG PDGFRA PDGFRB

Molecular functions related to Leiomyosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.7 DES MDM2 PGR S100A1 S100B TP53
2 MAP kinase kinase kinase activity GO:0004709 9.61 KIT PDGFRA PDGFRB
3 mitogen-activated protein kinase kinase binding GO:0031434 9.54 KIT PDGFRA PDGFRB
4 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.5 KIT PDGFRA PDGFRB
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.43 KIT PDGFRA PDGFRB
6 platelet-derived growth factor binding GO:0048407 9.4 PDGFRA PDGFRB
7 vascular endothelial growth factor binding GO:0038085 8.96 PDGFRA PDGFRB
8 growth factor binding GO:0019838 8.8 KIT PDGFRA PDGFRB
Sources

Sources for Leiomyosarcoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....